Table 12. Immune response to bivalent and quadrivalent HPV vaccines in females 18 to 45 years of age . (117,136).
| HPV2 (Cervarix™) | HPV4 (Gardasil®) | |||
|---|---|---|---|---|
| Anti-HPV type 16 | Anti-HPV type 18 | Anti-HPV type 16 | Anti-HPV type 18 | |
| Serum N GMT* ratio (ratio of type specifi response for Cervarix™/Gardasil®) | ||||
| Month 7 | 2.3-4.8x higher† | 6.8-9.1x higher† | ||
| Month 18 | 2.4-5.1x higher† | 7.9-9.8x higher† | ||
| Month 24 | 2.4-5.8x higher† | 7.7-9.4x higher† | ||
| Serum T-cells (% responders)** | ||||
| Month 7 | N/A | N/A | N/A | N/A |
| Month 18 | 92.5† | 78.6† | 40.0 | 42.4 |
| Month 24 | 90.9† | 74.3† | 60.0 | 40.0 |
| Serum B-cells (% responders)*** | ||||
| Month 7 | 89.8 | 88.7† | 94.3 | 66.1 |
| Month 18 | 86.7† | 74.5† | 58.6 | 45.2 |
| Month 24 | 83.3 | 76.3† | 66.7 | 52.9 |
| CVS nAb* | ||||
| Month 7 | 81.3† | 33.3† | 50.9 | 8.8 |
| Month 18 | 20.9 | 7.0 | 14.9 | 0.0 |
| Month 24 | 24.4 | 2.2 | 11.6 | 0.0 |
* measured by PBNA
** >500 specific CD4 T-cells expressing >2 of 4 immune markers; assay done on a subset of participants.
*** >0 specific memory B-cells per million cells; assay done on a subset of participants.
† Result is statistically significant.